Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market
I Río-Álvarez, E Cruz-Martos - Expert Opinion on Biological …, 2024 - Taylor & Francis
Introduction After 17 years on the market, biosimilar medicines have contributed significantly
to the sustainability of healthcare in Spain, providing cost-effective treatment options and …
to the sustainability of healthcare in Spain, providing cost-effective treatment options and …
Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study
HW Wong, VH Nguyen, TY Mok, F Niu, M Cushing… - BioDrugs, 2024 - Springer
Background Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-
CHOP) is one of the first line treatments for diffuse large B-cell lymphoma (DLBCL) …
CHOP) is one of the first line treatments for diffuse large B-cell lymphoma (DLBCL) …